INTI
Inhibitor Therapeutics, Inc.
Next earnings Aug 11, 2026
$0.08
▼ -12.22%$0.08▲ +68.09%
over 1Y
L $0.04H $0.12
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-12.2%
1W+2.6%
1M-6.0%
3M-12.2%
YTD+68.1%
1Y+68.1%
Hold
Conviction
Horizon
Medium (3–12mo)
High return on equity (255.5%).
Revenue (FY2021) $0.00 · FY2021
Inhibitor Therapeutics, Inc. shows $0.00 in FY2021 revenue, and 255.5% ROE.
Supporting the case: high return on equity (255.5%); conservative balance sheet (liabilities/equity -2.94x).
Is INTI a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~0.08
- Short call 0 @ ~0.00 est
debit $8max +−$8max −$8
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$325K | -$658K | -$3.40M | -$3.66M | -$3.43M |
| Net income | -$299K | $12.1M | -$3.03M | -$3.34M | -$3.30M |
| Diluted EPS | $0.00 | $0.03 | -$0.02 | -$0.02 | -$0.02 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$11.4M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-23.9%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$2.38M
Altman Z-Score-32.42 distress
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY+0.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-05-042026-06-24open ↗4Period ending 2026-05-052026-06-01open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-04-012026-04-01open ↗8-KPeriod ending 2026-04-012026-04-01open ↗10-KPeriod ending 2025-12-312026-03-26open ↗8-KPeriod ending 2026-02-242026-02-24open ↗10-QPeriod ending 2025-09-302025-11-13open ↗8-KPeriod ending 2025-10-242025-10-27open ↗UPLOADFiling2025-09-15open ↗10-QPeriod ending 2025-06-302025-08-13open ↗CORRESPFiling2025-07-22open ↗
Frequently asked
- Is Inhibitor Therapeutics, Inc. (INTI) a buy?
- INTI currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (255.5%).
- What is Inhibitor Therapeutics, Inc.'s quality score?
- INTI scores 37.40451021846371/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001042418, latest 10-Q filed 2026-05-15) · EODHD · as of 6/22/2026, 9:48:42 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 22, 2026, 5:48 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.